Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;13(1):8-13.
doi: 10.15420/icr.2017:21:1.

Transcatheter Treatment of Functional Tricuspid Regurgitation Using the Trialign Device

Christian Besler  1 , Christopher U Meduri  2 , Philipp Lurz  1
Affiliations

Transcatheter Treatment of Functional Tricuspid Regurgitation Using the Trialign Device

Christian Besler et al. Interv Cardiol. 2018 Jan.

Abstract

Functional tricuspid regurgitation (TR) represents an important unmet need in clinical cardiology given its prevalence, adverse prognostic impact and symptom burden associated with progressive right heart failure. Several transcatheter techniques are currently in early clinical testing to provide alternative treatment options for patients deemed unsuitable for tricuspid valve surgery. Amongst them, the TrialignTM device (Mitralign, Inc.) represents a novel percutaneous tricuspid valve annuloplasty technique, which aims to reduce tricuspid annular dilatation in functional TR by delivering and cinching two pledgeted sutures to the posterior portion of the tricuspid annulus via transjugular access. Early clinical data suggest the Trialign technique is safe and feasible, and associated with an improvement in quality-of-life measures. However, further studies are needed to confirm these data in larger cohorts of patients with longer follow up. In addition, future trials need to address the question whether TR reduction with the Trialign and other devices leads to an improvement in the patient`s functional status and prognosis, over and above medical treatment alone.

Keywords: Mitralign; Trialign; Tricuspid valve; right ventricle; transcatheter therapy; tricuspid regurgitation.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflict of interest to declare.

Figures

Figure 1:
Figure 1:. Changes of Tricuspid Annular Geometry in Functional Tricuspid Regurgitation
Figure 2:
Figure 2:. Anatomical Challenges in the Development of Transcatheter Techniques Targeting Functional Tricuspid Regurgitation
Figure 3:
Figure 3:. Pre-procedural Assessment of the Tricuspid Valve by Echocardiography
Figure 4:
Figure 4:. Percutaneous Tricuspid Valve Annuloplasty Using the Trialign System
Figure 5:
Figure 5:. Transcatheter Treatment of Severe Tricuspid Regurgitation With the Trialign Device
See this image and copyright information in PMC

References

    1. Rodés-Cabau J, Taramasso M, O’Gara PT. Diagnosis and treatment of tricuspid valve disease: current and future perspectives. Lancet. 2016;388:2431–42. doi: 10.1016/S0140-6736(16)00740-6. - DOI - PubMed
    1. Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg. 2006;132:1258–61. doi: 10.1016/j.jtcvs.2006.08.049. - DOI - PubMed
    1. Taramasso M, Vanermen H, Maisano F et al. The growing clinical importance of secondary tricuspid regurgitation. J Am Coll Cardiol. 2012;59:703–10. doi: 10.1016/j.jacc.2011.09.069. - DOI - PubMed
    1. Rogers JH, Bolling SF. The tricuspid valve: current perspective and evolving management of tricuspid regurgitation. Circulation. 2009;119:2718–25. doi: 10.1161/CIRCULATIONAHA.108.842773. - DOI - PubMed
    1. Najib MQ, Vinales KL, Vittala SS et al. Predictors for the development of severe tricuspid regurgitation with anatomically normal valve in patients with atrial fibrillation. Echocardiography. 2012;29:140–6. doi: 10.1111/j.1540-8175.2011.01565.x. - DOI - PubMed

LinkOut - more resources